Zhou Xionghongcan, Wang Lihua, Wu Yayang, Lin Xiaoping, Liu Fen, Sun Xiaoxia, Song Kaiyue, Jiang Cong, Zhao Feng, Li Xianglong
Jiangxi Provincial Key Laboratory of Organic Functional Molecules, Institute of Organic Chemistry, Jiangxi Science and Technology Normal University, Nanchang, 330013, China.
Institute of New Energy Materials Engineering, School of New Energy Industry, Jiangxi Hongzhou Vocational College, YiChun, 331100, China.
Mater Today Bio. 2025 May 13;32:101864. doi: 10.1016/j.mtbio.2025.101864. eCollection 2025 Jun.
Cancer immunotherapy, which activates the patient's immune system to combat tumors, has made significant progress in recent years. However, the immunosuppressive nature of the tumor microenvironment and the side effects associated with systemic administration limit its efficacy. Taking advantage of bioactive polydopamine (PDA) materials in controlled drug and immunomodulator release owing to their unique physicochemical properties and biocompatibility, recent efforts have focused on engineered PDA nanomedicines with intrinsic immunomodulatory functions, but relevant systematic reviews are lacking. This review summarizes recent advances in the application of bioactive PDA nanomedicines in cancer immunotherapy, focusing on their roles in inducing immunogenic cell death, reprogramming tumor-associated macrophages, as cancer vaccine, and enhancing immune checkpoint blockade. With further in-depth discussion of the challenges and future perspectives of bioactive PDA nanomedicines, with the aim that this systematic review can promote interdisciplinary intersections and provide inspiration for the further growth and clinical translation of PDA materials.
癌症免疫疗法可激活患者的免疫系统以对抗肿瘤，近年来已取得显著进展。然而，肿瘤微环境的免疫抑制特性以及全身给药相关的副作用限制了其疗效。由于具有独特的物理化学性质和生物相容性，生物活性聚多巴胺（PDA）材料在药物和免疫调节剂的控释方面具有优势，最近的研究重点是具有内在免疫调节功能的工程化PDA纳米药物，但缺乏相关的系统综述。本综述总结了生物活性PDA纳米药物在癌症免疫疗法中的应用进展，重点关注它们在诱导免疫原性细胞死亡、重编程肿瘤相关巨噬细胞、作为癌症疫苗以及增强免疫检查点阻断方面的作用。通过进一步深入讨论生物活性PDA纳米药物面临的挑战和未来前景，旨在使本系统综述能够促进跨学科交叉，并为PDA材料的进一步发展和临床转化提供灵感。
